

INFORMATION DISCLOSURE  
CITATION

ATTY. DOCKET NO.

SERIAL NO.

622-39

09/524,747

APPLICANT

REINER et al


FILING DATE

GROUP

March 15, 2000

1623

(Use several sheets if necessary)



## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
						NOV 06 2003
						TECH CENTER 1600/2900

## FOREIGN PATENT DOCUMENTS

DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
6 0 466 650 A2	01/1992	EP			

## OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

8/0	1	Henry, D., et al; "Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis"; BMJ; Vol. 312, pp. 1563-1566, (1996).
8/0	2	Walker, A.M.; "Quantitative studies of the risk of serious hepatic injury in persons using nonsteroidal antiinflammatory drugs"; Arthritis and Rheumatism, Vol. 40, No. 2, pp. 201-208 (1997).
8/0	3	Gutthann, S.P., et al; "Nonsteroidal anti-inflammatory drugs and the risk of hospitalization for acute renal failure"; Arch. Intern. Med., Vol. 156, pp. 2433-2439, (1996)
8/0	4	Amidon, G.L., et al; "A theoretical basis for a biopharmaceutic drug classification: The correlation of <i>in vitro</i> drug product dissolution and <i>in vivo</i> bioavailability"; Pharm. Research, Vol. 12, No. 3, pp. 413-420, (1995).
8/0	7	Neuvonen, P.J., "The effect of magnesium hydroxide on the oral absorption of ibuprofen, ketoprofen and diclofenac"; Br. J. Clin. Pharmacol. Vol. 31, pp. 263-266, (1991).
8/0	8	Neuvonen, P.J., et al; "Enhancement of drug absorption by antacids"; Clin. Pharmacokinet. 27 (2): pp. 120-128, (1994).
8/0	9	Neuvonen, P.J., et al; "Effect of magnesium hydroxide on the absorption of tolfenamic and mefenamic acids"; Eur. J. Clin. Pharmacol. 35: pp. 495-501, (1988).
8/0	10	Derendorf, H., et al; "Pharmacokinetics of diclofenac sodium after intramuscular administration in combination with triamcinolone acetate"; Eur. J. Clin. Pharmacol., 31:363-365 (1986).
8/0	11	Terhaag, B., et al; "Bioavailability of a new effervescent tablet of diclofenac"; Int. J. Clin. Pharmacol. Ther., 38:546:551 (2000).
8/0	12	Lotsch, J., et al.; "Population pharmacokinetics of fast release oral diclofenac in healthy volunteers: relation to pharmacodynamics in an experimental pain model"; Pharmaceutical Research, Vol. 17, No. 1, pp. 77-84, (2000).
8/0	13	Marzo, A., et al; "Pharmacokinetics of Diclofenac after oral administration of its potassium salt in sachet and tableted formulations"; Arzneimittel. Forsch., 50:43-47 (2000).
8/0	14	Reiner, V., et al; "Increased absorption rate of diclofenac from fast acting formulations containing its potassium salt"; Arzneimittel. Forsch., 51:885-890 (2001).
8/0	15	Fourtillan, J.B., et al; "Etude pharmacocinetique du piroxicam chez l'homme sain", Therapie, Vol. 38, pp. 163-170, (1983).
8/0	16	Brogden, R.N., et al; "Diclofenac sodium: A review of its pharmacological properties and therapeutic use in rheumatic diseases and pain of varying origin"; Drugs, 20: pp. 24-48, (1980).
8/0	17	Macia, M.A., et al; "Comparative bioavailability of a dispersible formulation of diclofenac and finding of double plasma peaks"; Int. J. Clin Pharmacol. Ther., 33:333-339 (1995).

\*Examiner

Date Considered

2/9/04

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

## INFORMATION DISCLOSURE CITATION

ATTY. DOCKET NO.

622-39

**SERIAL NO.**

09/524,747

**APPLICANT**

REINER et al

FILING DATE

March 15, 2000

**GROUP**

1623

(Use several sheets if necessary)

~~NOV 03 2003~~

- |    |   |
|----|---|
| Ho | 18 Berman, R., et al; "Swelling force development as a result of hydrate formation in diclofenac sodium or nitrofurantoin tablets"; S.T.P. Pharma Sciences 10 (4) pp. 335-339, (2000).        |
| Ho | 19 Henrikson, P.A., et al; "Absorption and effect of diclofenac sodium after surgical removal of a lower wisdom tooth; Curr. Ther. Res., 31:30-26 (1982).                                     |
| Ho | 20 Degen, P.H., et al; "Pharmacokinetics of diclofenac and five metabolites after single doses in healthy volunteers and after repeated doses in patients"; Xenobiotica, 18:1449-1455 (1988). |
| Ho | 21 Maggi, C.A., et al; "Comparative bioavailability of diclofenac hydroxyethylpyrrolidine vs diclofenac sodium in man"; Eur. J. Clin. Pharmacol., 38:207-208 (1990).                          |
| Ho | 22 Mendes, G.B.B., et al; "Comparative bioavailability of two suspension formulations of potassium diclofenac in healthy male volunteers"; Int. J. Clin. Pharmacol. Ther., 32:131-135 (1994). |
| Ho | 23 Crook, P.R., et al; "The pharmacokinetics of diclofenac sodium in patients with active rheumatoid disease"; Eur. J. Clin. Pharmacol., 21:331-334 (1982).                                   |
| Ho | 24 Willis, J.V., et al; "The pharmacokinetics of diclofenac sodium following intravenous and oral administration"; Eur. J. Clin. Pharmacol., 16:405-410 (1979).                               |
| Ho | 25 Willis, J.V., et al; "The influence of food on the absorption of diclofenac after single and multiple oral doses"; Eur. J. Clin. Pharmacol., 19:33-37 (1981).                              |
| Ho | 26 Riess, W., et al; "Pharmacokinetics and metabolism of the anti-inflammatory agent Voltalein" Scand. J. Rheumatol., Suppl. 22:17-29 (1978).   |
| Ho | 27 Physicians' Desk Reference; Novartis Pharmaceutical Corp., pp. 1830-1832 (2000).   |

**RECEIVED**

~~NOV 06 2003~~

TECH CENTER 1600/2900

**\*Examiner**

Date Considered

2/9/04

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.